These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 28554514)

  • 21. Monocrotaline-induced pulmonary hypertension in Wistar rats.
    Rey M; Hess P; Clozel M
    Curr Protoc Pharmacol; 2009 Sep; Chapter 5():Unit 5.56. PubMed ID: 22294402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure.
    Buermans HP; Redout EM; Schiel AE; Musters RJ; Zuidwijk M; Eijk PP; van Hardeveld C; Kasanmoentalib S; Visser FC; Ylstra B; Simonides WS
    Physiol Genomics; 2005 May; 21(3):314-23. PubMed ID: 15728335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.
    Andersen A; Nielsen JM; Holmboe S; Vildbrad MD; Nielsen-Kudsk JE
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):167-73. PubMed ID: 23575263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of TNF-alpha blockade in monocrotaline-induced pulmonary hypertension.
    Henriques-Coelho T; Brandão-Nogueira A; Moreira-Gonçalves D; Correia-Pinto J; Leite-Moreira AF
    Rev Port Cardiol; 2008 Mar; 27(3):341-8. PubMed ID: 18551920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the nicotinamide N-methyltransferase (NNMT)-1-methylnicotinamide (MNA) pathway in pulmonary hypertension.
    Fedorowicz A; Mateuszuk Ł; Kopec G; Skórka T; Kutryb-Zając B; Zakrzewska A; Walczak M; Jakubowski A; Łomnicka M; Słomińska E; Chlopicki S
    Respir Res; 2016 Aug; 17(1):108. PubMed ID: 27581040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of chronic treprostinil treatment on experimental right heart hypertrophy and failure.
    Axelgaard S; Holmboe S; Ringgaard S; Hillgaard TK; Andersen S; Hansen MS; Andersen A; Nielsen-Kudsk JE
    Cardiol Young; 2017 Jan; 27(1):90-100. PubMed ID: 27087410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiology of infantile pulmonary arterial hypertension induced by monocrotaline.
    Dias-Neto M; Luísa-Neves A; Pinho S; Gonçalves N; Mendes M; Eloy C; Lopes JM; Gonçalves D; Ferreira-Pinto M; Leite-Moreira AF; Henriques-Coelho T
    Pediatr Cardiol; 2015 Jun; 36(5):1000-13. PubMed ID: 25608696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of renovascular hypertension on repolarization of ventricular epicardium.
    Krandycheva VV; Kharin SN; Azarov JE; Shmakov DN
    Exp Clin Cardiol; 2009; 14(2):e51-6. PubMed ID: 19675821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
    J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salubrinal attenuates right ventricular hypertrophy and dysfunction in hypoxic pulmonary hypertension of rats.
    He YY; Liu CL; Li X; Li RJ; Wang LL; He KL
    Vascul Pharmacol; 2016 Dec; 87():190-198. PubMed ID: 27678416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocardial structural, contractile and electrophysiological changes in the guinea-pig heart failure model induced by chronic sympathetic activation.
    Soltysinska E; Olesen SP; Osadchii OE
    Exp Physiol; 2011 Jul; 96(7):647-63. PubMed ID: 21571815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
    Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
    J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure.
    Stambler BS; Laurita KR; Shroff SC; Hoeker G; Martovitz NL
    Heart Rhythm; 2009 Jun; 6(6):776-83. PubMed ID: 19427273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension.
    Okada K; Tanaka Y; Bernstein M; Zhang W; Patterson GA; Botney MD
    Am J Pathol; 1997 Oct; 151(4):1019-25. PubMed ID: 9327735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure.
    Piao L; Marsboom G; Archer SL
    J Mol Med (Berl); 2010 Oct; 88(10):1011-20. PubMed ID: 20820751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Right ventricular failure secondary to chronic overload in congenital heart disease: an experimental model for therapeutic innovation.
    Lambert V; Capderou A; Le Bret E; Rücker-Martin C; Deroubaix E; Gouadon E; Raymond N; Stos B; Serraf A; Renaud JF
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1197-204, 1204.e1. PubMed ID: 20412956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
    Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
    Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered proteasome function in right ventricular hypertrophy.
    Heitmeier T; Sydykov A; Lukas C; Vroom C; Korfei M; Petrovic A; Klingel K; Günther A; Eickelberg O; Weissmann N; Ghofrani HA; Seeger W; Grimminger F; Schermuly RT; Meiners S; Kosanovic D
    Cardiovasc Res; 2020 Feb; 116(2):406-415. PubMed ID: 31020333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of myocardial hypertrophy on acute and chronic right ventricular performance in relation to chronic volume overload in a porcine model: relevance for the surgical management of tetralogy of Fallot.
    Bove T; Vandekerckhove K; Bouchez S; Wouters P; Somers P; Van Nooten G
    J Thorac Cardiovasc Surg; 2014 Jun; 147(6):1956-65. PubMed ID: 24280710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.